FOLH1 and prostate carcinoma: Considering that PSMA theranostics will soon become a standard of care in the management of prostate cancer, it will be crucial to integrate nuclear medicine physicians into the multidisciplinary team alongside medical oncologists, radiation oncologists, urologists, and radiologists in order to optimize the care of patients with this complex malignancy.